Publications

5891 Results

An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: initial report of RTOG 94-02

Authors
G Cairncross;W Seiferheld;E Shaw;R Jenkins;B Scheithauer;D Brachman;J Buckner;K Fink;L Souhami;W Curran
Journal / Conference
Proc of the American Society of Clinical Oncology 23:107 (#1500)
Year
2004
Research Committee(s)
Brain
Study Number(s)
SWOG-9402

Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): a model for prospective comparison of cooperative group trials

Authors
DR Gandara;Y Ohe;K Kubota;Y Nishiwaki;Y Ariyoshi;N Saijo;S Williamson;PN Lara;J Crowley;M Fukuoka
Journal / Conference
Proc of the American Society of Clinical Oncology 23:616 (#7007)
Year
2004
Research Committee(s)
Lung
Study Number(s)
S0003

Interferon Alpha-2b and thalidomide in previously treated patients with disseminated malignant melanoma: SWOG 0026

Authors
L Hutchins;J Moon;J Clark;J Thompson;K Yost;V Sondak
Journal / Conference
Proc of the American Society of Clinical Oncology 23:713 (#7527)
Year
2004
Research Committee(s)
Melanoma
Study Number(s)
S0026

A phase II evaluation of a 3-hour infusion of paclitaxel (P), cisplatin (CDDP) & 5-fluorouracil (5FU) in patients with advanced or recurrent squamous cell carcinoma of the head and neck (SCCHN). A Southwest Oncology Group (SWOG) study

Authors
FP Worden;J Moon;W Samlowski;J Clark;SR Dakhil;SA Taylor;SG Urba;M Hussain
Journal / Conference
Proc of the American Society of Clinial Oncology 23:489 (#5512)
Year
2004
Research Committee(s)
Head and Neck
Study Number(s)
S0007

Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: a SWOG phase II trial (S0027)

Authors
PJ Hesketh;K Chansky;DH Lau;J Crowley;DR Gandara
Journal / Conference
Proc of the American Society of Clinical Oncology 23:627 (#7056)
Year
2004
Research Committee(s)
Lung
Study Number(s)
S0027

Dose effect of imatinib (IM) in patients (pts) with metastatic GIST-phase III sarcoma group study S0033

Authors
C Rankin;M von Mehren;C Blanke;R Benjamin;CDM Fletcher;V Bramwell;J Crowley;GD Demetri
Journal / Conference
Proc of the American Society of Clinical Oncology 23:815 (#9005)
Year
2004
Research Committee(s)
Sarcoma
Study Number(s)
S0033

A phase II trial of epothilone B analogue BMS-247550 (NSC# 710428) in patients with advanced pancreas cancer: a Southwest Oncology Group study

Authors
RP Whitehead;SA McCoy;SE Rivkin;HM Gross;ME Conrad;JL Abbruzzese
Journal / Conference
Proc of the American Society of Clinical Oncology 23:315 (4012)
Year
2004
Research Committee(s)
Gastrointestinal
Study Number(s)
S0107

Epothilone B (Epo-B) analogue BMS-247550 (NSC# 710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). a Southwest Oncology Group study (S0111)

Authors
M Hussain;J Faulkner;U Vaishampayan;P Lara;D Petrylak;D Colevas;W Sakr;ED Crawford
Journal / Conference
Proc of the American Society of Clinical Oncology 23:383 (#4510)
Year
2004
Research Committee(s)
Genitourinary
Study Number(s)
S0111

Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) study S0126.

Authors
H West;WA Franklin;PH Gumerlock;RB Vance;DHM Lau;J McCoy;J Crowley;DR Gandara
Journal / Conference
Proc of the American Society of Clinical Oncology 23:618 (#7014)
Year
2004
Research Committee(s)
Lung
Study Number(s)
S0126

Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM)

Authors
L Garland;C Rankin;K Scott;R Nagle;M Lobell;D Gandara;S Rivkin;W Samlowski;J Atkins;E Borden
Journal / Conference
Proc of the American Society of Clincial Oncology 23:196 (#3007)
Year
2004
Research Committee(s)
Lung
Study Number(s)
S0218